Hemab Therapeutics (NASDAQ:COAG) Reaches New 52-Week High – Should You Buy?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) hit a new 52-week high during trading on Monday . The stock traded as high as $51.00 and last traded at $51.00, with a volume of 4884 shares traded. The stock had previously closed at $49.29.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on COAG shares. The Goldman Sachs Group began coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective for the company. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Jefferies Financial Group upped their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, July 13th. HC Wainwright raised their price target on shares of Hemab Therapeutics from $40.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Wedbush restated an “outperform” rating and set a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a report on Monday, July 13th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.00.

Hemab Therapeutics Trading Up 4.9%

The business’s fifty day moving average is $30.22. The stock has a market capitalization of $2.41 billion and a PE ratio of -2.16.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Insider Buying and Selling

In other news, Director Ra Capital Management, L.P. bought 2,675,000 shares of Hemab Therapeutics stock in a transaction that occurred on Monday, May 4th. The stock was purchased at an average cost of $18.00 per share, with a total value of $48,150,000.00. Following the completion of the transaction, the director directly owned 6,149,096 shares in the company, valued at $110,683,728. This trade represents a 77.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired 2,970,541 shares of company stock valued at $55,459,603 over the last three months.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.